Investigators
Study information
- Research Area: HIV
- Research type: Longitudinal study
- Start date: Jun 01, 2020
- End date: Sep 30, 2023
Study aim of the objectives
Main objective: To determine the safety profile of DTG-based regimens including TDF/3TC/DTG and ABC/3TC+DTG among HIV patients in Rwanda
Specific objectives:
1. To characterize adverse event (AE) and adverse drug reaction (ADR) profiles among patients using DTG-based regimens
2. To determine the incidence rate for AEs, in patients using DTG-based regimens
3. To assess causality between observed AEs and the use of DTG-based regimens
4. To determine the effect of DTG-based regimens on weight gain as well as the blood glucose and lipid profiles
5. To identify risk factors for AE/ADR development and determine their effect on AE/ADR incidence and severity among patients using DTG-based regimens
6. To propose possible interventions to prevent AEs and ADRs associated with the use of DTG-based regimens where applicable
Study setting/Area (Location)
Selected sentinels
Implementing institution
RBC & MSH
Department/Division
HIV Care and Treatment Unit
Impact on Policy
To inform guideline and policies to improve the management of people living with HIV